



Buying Reagents from ATCC—What Are You Really Agreeing to?

If you are under the impression that reagents purchased from ATCC come with “no strings” attached and can be freely distributed, guess again. The reagents purchased through ATCC, as well as any modifications (a substance that contains or incorporates the original material) you make, may not be transferred to any other investigator inside or outside of St. Jude without permission from ATCC. This restriction on the use and distribution of materials protects the original depositors’ rights.

Many researchers are unaware of the restrictions placed upon the materials since no agreement is signed when the materials are purchased. However, all ATCC orders are governed by the standard Material Transfer Agreement (MTA) listed on their Web site at <http://www.atcc.org/MaterialTransferAgreement/tabid/613/Default.aspx>. The MTA conditions include but are not limited to:

- the materials may be used for research purposes only and only in the investigator’s lab,

- the materials and modifications may not be distributed, sold or transferred without the prior written consent of ATCC,
- the materials may not be used for any commercial purposes without the prior written approval of ATCC, and
- the materials are not intended for use in humans.

While the prior written approval of ATCC is generally necessary in order to transfer materials and modifications to third parties, ATCC has not objected to our use of a special MTA for transfers of modifications made at St. Jude to other academic institutions. This MTA states that the modified ATCC materials will be used for research purposes only and will not be transferred to third parties. It further states that the recipient will purchase the original material from ATCC prior to signing the MTA.

Before you share your newly-modified ATCC cell line, please contact Esther Allay in the OTL to get the proper permission in place prior to the transfer.

Thank You

A critical factor in the success of any technology licensing operation is the participation and cooperation of its researchers. Without a steady flow of new ideas and materials to patent and license, a technology licensing office cannot be successful no matter how hard it tries.

The Office of Technology Licensing (OTL) is privileged to have great participation and cooperation from the researchers here at St. Jude. We receive between 35 and 50 invention disclosures each year, which translates into an average submission rate of one invention disclosure every 2–3 years by each researcher. To show our appreciation, we would like to acknowledge the individuals listed on page 2 who took the time to submit their ideas during fiscal year 2009.

Researchers Who Submitted Ideas in FY2009

Jerry Aldridge
 Suzanne Baker
 Nader Chalhoub
 Hongbo Chi
 Samantha Cicero
 Lauren Collison
 Robert Daniel
 Alessandra d'Azzo
 Dario Campana
 Elaine Coustan-Smith
 Michael Dyer
 Paolo Fagone
 Clementine Feau
 Richard Gilbertson
 David Grandy
 John Gray
 Douglas Green

Gerard Grosveld
 Kip Guy
 Claudia Hillenbrand
 Peter Houghton
 Michael Kastan
 Jill Lahti
 Christy Laurenzi
 Ralf Loeffler
 Dean Madden
 Henju Marjuki
 Stephan Morris
 Carson Moseley
 John Nitiss
 James Owens
 Zoltan Patay
 Tremaine Powell
 Martine Roussel

John Schuetz
 Jufang Shan
 Charles Sherr
 Matthew Smeltzer
 David Smithson
 Ruitian Song
 Paul Taylor
 Dario Vignali
 Robert Webster
 Michisuke Yuzaki
 Steve Zatechka
 Thirumala-Devi Kanneganti
 Thomas Webb
 Gerard Zambetti
 Jie Zheng

OTL Activities

A summary of FY09 OTL activities is shown in Figures 1 and 2 below and the tables found on the following page. The number of invention disclosures, patents granted and applications filed over the last five fiscal years are shown in Figure 1. All numbers are in line with expectations when compared to previous years, except for the increase in the number of foreign patents granted in FY09. This increase is due primarily to patents issued on St. Jude's DNA transfection system for the generation of infectious influenza virus. Figure 2 shows a breakdown of the number of agreements executed by the OTL over the last five years. The overall number of agreements increased by 42% over FY08. The tables on the following page show information related to U.S patents issued and patent applications filed during FY09.





Figure 1. Patent activity (2005-2009)

Figure 2. OTL Agreements (2005-2009)

U.S. Patents Issued to St. Jude During FY2009

Patent #	Issue Date	Subject Matter	Inventor(s)
7,425,615	9/16/08	Protein specific for cardiac and skeletal muscle	Alessandra d'Azzo, Antonella Bongiovanni, Tommaso Nastasi
7,435,596	10/14/08	Chimeric receptors with 4-1BB stimulatory signaling domain	Dario Campana, Chihaya Imai
7,452, 717	11/18/08	Compositions and methods for sensitizing and inhibiting growth of human tumor cells	Mary Danks, Peter Houghton, Philip Potter
7,479,282	1/20/09	A polypeptide comprising the amino acid of an N-terminal choline binding protein A truncate, vaccine derived therefrom and uses thereof	Elaine Tuomanen
7,517,890	4/14/09	GTPase inhibitors and methods of use	Jie Zheng, John Dickerson

St. Jude U.S. Patent Applications Filed During FY2009

Date Filed	St. Jude Inventor(s)	Department	Patent Title
8/22/08	Jie Zheng, Jufang Shan, David Grandy	Structural Biology	Inhibitors of Dishevelled Protein
9/8/08	Dario Campana, Chihaya Imai	Oncology	Chimeric Receptors with 4-1BB Stimulatory Signaling Domain
10/17/08	Kip Guy, Yiqun Zhang	Chemical Biology	Chemical series for the treatment of malaria
12/12/08	Michael Kastan, Christopher Bakkenist	Cancer Center	Critical phosphorylation site for activation of ATM kinase
12/22/08	Philip Potter, Monika Wierdl	Molecular Pharmacology	mutant hCE
12/22/08	Jie Zheng	Structural Biology	DKK2 in E. coli
1/12/09	Michael Dyer	Developmental Neurobiology	Treatment of Retinoblastoma with p53 modulators
1/21/09	Jerry Aldridge, Carson Moseley	Infectious Diseases	Methods for Suppressing tipDC Trafficking
2/23/09	Thomas Webb, Peter Slavish	Chemical Biology	A new kinase inhibitor scaffold for ALK and IGFR
2/27/09	Kip Guy	Chemical Biology	Anti-malarial 4- aminoquinolines
3/3/09	Dario Vignali, Lauren Collison	Immunology	Use of iL-35 to convert T-cells to regulatory T-cells
3/5/09	Richard Webby, Adrianus Boon	Infectious Diseases	Humanized Influenza Antibodies
3/13/09	Dario Vignali, Creg Workman, Lauren Collison, Kathleen Vignali	Immunology	IL-35
3/19/09	Elaine Tuomanen, Richard Kriwacki	Infectious Diseases, Structural Biology	Synthetic <i>Streptococcus pneumoniae</i> vaccine
3/23/09	Xiaohua Chen, Rupert Handgretinger, Geoffrey Neale	Bone Marrow Transplant and Cellular Therapy	Methods and Composition for Monitoring T-cell Receptor Diversity
4/14/09	Jonathan McCullers, Julia Hurwitz, Karen Slobod, Victor Huber	Infectious Diseases	Universal Influenza Vaccine
4/15/09	Linda Hendershot, Yuichiro Shimizu	Genetics and Tumor Cell Biology	ERp23
4/27/09	William Evans	Pharmaceutical Sciences	RNA-supported complementation of a split protein toxin for targeted destruction of pathological mammalian cells
5/22/09	Jie Zheng, Jufang Shan	Structural Biology	NMR structure of Dkk

OTL Staff • J. Scott Elmer, Director, x2756; Shawn A. Hawkins, Associate Director, x2751; Esther R. Allay, Licensing Associate, x4700; Regina D. McKinney, Executive Associate, x5354; Sheila R. Wilson, Administrative Assistant, x2342